RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer
NCT03699956
Terminated
This Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
03/22/2024
Locations: Cotton O'Neil Clinical Research Center.Hematology & Oncology, Topeka, Kansas +1 locations
Conditions: Carcinoma, Small Cell Lung
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT06322693
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Wichita, Kansas
Conditions: Neoplasms
Register for Updates
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
NCT01196390
Completed
This randomized phase III trial studies how well radiation therapy, paclitaxel, and carboplatin with or without trastuzumab work in treating patients with esophageal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2023
Locations: University of Kansas Cancer Center-West, Kansas City, Kansas +6 locations
Conditions: Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIB Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7
Register for Updates
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT01107626
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of non-small cell lung cancer by bloc... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Providence Medical Center, Kansas City, Kansas +3 locations
Conditions: Lung Cancer
Register for Updates
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer
NCT00014118
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by radiation therapy and chemotherapy in treating patients who have stage III or stage IV cancer of the larynx or stage III or stage IV cancer of the oro... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/14/2023
Locations: Cancer Center of Kansas, PA - Chanute, Chanute, Kansas +16 locations
Conditions: Head and Neck Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00041314
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of carboplatin, gemcitabine, and exisulind in treating patients who have advanced non-small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/13/2023
Locations: CCOP - Wichita, Wichita, Kansas +1 locations
Conditions: Lung Cancer
Register for Updates
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
NCT00632853
Active Not Recruiting
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer. This randomized phase III trial is comparing different chest radiation... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/08/2023
Locations: Cancer Center of Kansas - Chanute, Chanute, Kansas +26 locations
Conditions: Lung Cancer
Register for Updates
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
NCT00946712
Terminated
This randomized phase III trial studies carboplatin and paclitaxel to compare how well they work with or without bevacizumab and/or cetuximab in treating patients with stage IV or non-small cell lung cancer that has returned after a period of improvement (recurrent). Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2023
Locations: Cancer Center of Kansas - Chanute, Chanute, Kansas +40 locations
Conditions: Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Squamous Cell Lung Carcinoma, Stage IV Large Cell Lung Carcinoma, Stage IV Lung Adenocarcinoma, Stage IV Squamous Cell Lung Carcinoma
Register for Updates
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
NCT02983045
Completed
In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D. Part 2 considered dose expansion cohorts for the doublet (NKTR 214 + nivolumab ± chemotherapy). Part 3 was schedule-finding for a triplet therapy (NKTR 214 + nivolumab + ipilimumab). Part 4 dose expansion for the triplet (NKTR 214 + nivolumab + ipilimumab) was planned to further asses... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/09/2023
Locations: University of Kansas Cancer Center, Kansas City, Kansas
Conditions: Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer
Register for Updates
Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
NCT02659059
Completed
The purpose of part 1 of this study is to determine the objective response rate (ORR) in stage IV NSCLC subjects treated with nivolumab in combination with ipilimumab as first line therapy. The purpose of part 2 of this study is to determine the safety and tolerability of nivolumab and ipilimumab combined with a short course of chemotherapy in first line stage IV NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2023
Locations: Cancer Center Of Kansas, Wichita, Kansas
Conditions: Non-Small-Cell Lung Cancer
Register for Updates
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03038100
Completed
This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will undergo neoadjuvant therapy followed by i... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/15/2023
Locations: University of Kentucky; Gynecologic Oncology, Lexington, Kansas
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Register for Updates
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
NCT03321188
Unknown
This study will evaluate the use of Heated Intraperitoneal Chemotherapy (HIPEC) for primary treatment of ovarian cancer at the time of surgical debulking, to assess if intravenous (IV) chemotherapy can be started within 42 days of HIPEC and cytoreduction. All patients will receive cytoreductive surgery followed by a one-time closed HIPEC with cisplatin at 41-43 degrees Celsius for 90 minutes in the operating room. This is followed by 6 cycles of intravenous carboplatin and paclitaxel on an outpa... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/03/2023
Locations: The University of Kansas Cancer Center, Kansas City, Kansas
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
Register for Updates